Addition of Rituximab to Involved-Field Radiation Therapy Prolongs Progression-free Survival in Stage I-II Follicular Lymphoma: Results of a Multicenter StudyMarco Ruella, Liliana Devizzi, Andrea Riccardo Filippi et al.|International Journal of Radiation Oncology*Biology*Physics|2015Cited by 48
Long-Term Results of Autologous Hematopoietic Stem-Cell Transplantation After High-Dose <sup>90</sup>Y-Ibritumomab Tiuxetan for Patients With Poor-Risk Non-Hodgkin Lymphoma Not Eligible for High-Dose BEAMLiliana Devizzi, Alessandro M. Gianni, Massimo Di Nicola et al.|Journal of Clinical Oncology|2013Cited by 14
The Risk of Secondary Myelodysplastic Syndrome/Acute Leukemia Following High-Dose Yttrium-90 Ibritumomab Tiuxetan Is Analogous to That Observed Following High-Dose Chemotherapy: a Matched-Pair Analysis In Non-Hodgkin Lymphoma Patients.Anna Guidetti, Alessandro M. Gianni, Alessandra Risso et al.|Blood|2010Cited by 1